Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Sisram Medical Ltd. ( (HK:1696) ) is now available.
Sisram Medical Ltd. announced a planned internal reorganisation at its controlling shareholder Fosun Pharma, under which two indirect wholly owned subsidiaries, Ample Up Limited and Chindex Medical Limited, will transfer their entire combined 71.42% stake in Sisram to another Fosun unit, Fosun Pharma Industrial Pte. Ltd. The restructuring, which is subject to certain conditions, will consolidate Fosun Pharma’s majority holding under a single subsidiary without changing its overall 71.42% indirect equity interest, supported by a regulator-granted waiver from the usual mandatory general offer requirement.
The move is intended to optimize Fosun Pharma’s internal shareholding structure in Sisram Medical and streamline control at the holding-company level. For Sisram and its minority shareholders, the transaction is not expected to alter day-to-day operations or the balance of power, as the ultimate controlling shareholder, voting rights concentration, and total number of shares held by Fosun Pharma remain unchanged following completion.
The most recent analyst rating on (HK:1696) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
More about Sisram Medical Ltd.
Sisram Medical Ltd., incorporated in Israel and listed in Hong Kong, operates in the medical technology sector. The company is controlled by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., which holds a majority stake through its network of indirect wholly owned subsidiaries.
Average Trading Volume: 366,811
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.56B
Learn more about 1696 stock on TipRanks’ Stock Analysis page.